Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Common X-chromosome variants are associated with Parkinson’s disease risk

View ORCID ProfileYann Le Guen, View ORCID ProfileValerio Napolioni, Michael E. Belloy, View ORCID ProfileEric Yu, Lynne Krohn, Jennifer A. Ruskey, Ziv Gan-Or, Gabriel Kennedy, Sarah J. Eger, Michael D. Greicius
doi: https://doi.org/10.1101/2020.12.18.20248459
Yann Le Guen
1Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, 94305, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Yann Le Guen
  • For correspondence: yleguen@stanford.edu
Valerio Napolioni
2School of Biosciences and Veterinary Medicine, University of Camerino, Camerino, 62032, Italy
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Valerio Napolioni
Michael E. Belloy
1Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, 94305, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Yu
3Department of Human Genetics, McGill University, Montréal, QC, Canada
4Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Eric Yu
Lynne Krohn
3Department of Human Genetics, McGill University, Montréal, QC, Canada
4Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer A. Ruskey
4Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada
5Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ziv Gan-Or
3Department of Human Genetics, McGill University, Montréal, QC, Canada
4Montreal Neurological Institute and Hospital, McGill University, Montréal, QC, Canada
5Department of Neurology and Neurosurgery, McGill University, Montréal, QC, Canada
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gabriel Kennedy
1Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, 94305, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sarah J. Eger
1Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, 94305, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Michael D. Greicius
1Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA, 94305, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Objective Identify genetic variants on the X-chromosome associated with Parkinson’s disease (PD) risk.

Methods We performed an X-chromosome-wide association study (XWAS) of PD risk by meta-analyzing results from sex-stratified analyses. To avoid spurious associations, we designed a specific harmonization pipeline for the X-chromosome and focused on a European ancestry sample. We included 11,324 cases, 280,060 controls, and 5,379 proxy cases, based on parental history of PD. Additionally, we tested the association of significant variants with: (i) PD risk in an independent replication with 1,564 cases and 2,467 controls, and (ii) putamen volume in 33,360 individuals from the UK Biobank.

Results In the discovery meta-analysis, we identified: rs7066890 (OR=1.10 [1.06-1.14]; P=2.2×10−9) intron of GPM6B, and rs28602900 (OR=1.10 [1.07-1.14]; P=1.6×10−8) in a high gene density region including RPL10, ATP6A1, FAM50A, PLXNA3. The rs28602900 association with PD was replicated (OR=1.16 [1.03-1.30]; P=0.016) and shown to colocalize with a significant expression quantitative locus (eQTL) regulating RPL10 expression in the putamen and other brain tissues in GTEx. Additionally, the rs28602900 locus was found to be associated with reduced brain putamen volume. No results reached genome-wide significance in the sex-stratified analyses.

Interpretation We report the first XWAS of PD and identify two genome-wide significant loci. The rs28602900 association replicated in an independent PD dataset and showed concordant effects in its association with putamen volume. Critically, rs26802900 is a significant eQTL of RPL10.These results support a role for ribosomal proteins in PD pathogenesis and show that the X-chromosome contributes to PD genetic risk.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

Funding for this study was provided by the Iqbal Farrukh and Asad Jamal Center for Cognitive Health in Aging, and the NIH (AG060747 and AG047366). ZGO is supported by the Fonds de recherche du Québec - Santé (FRQS) Chercheurs-boursiers award, in collaboration with Parkinson Quebec, and by the Young Investigator Award by Parkinson Canada. We would like to thank all of the subjects who donated their time and biological samples to be a part of this study. Acknowledgment for the use of PD datasets PD data included the International Parkinson's Disease Consortium (IPDGC), NeuroX dataset provided through dbGaP accession phs000918.v1.p1. We thank the IPDGC and the funding source 100064005, 11348001. National Institute of Neurological Disorders and Stroke, National Institute on Aging, National Institutes of Health, Bethesda, MD, and United States Army Medical Research Acquisition Activity (USAMRAA), Fort Detrick, MD, Department of Defense, DC, USA. (PI Andrew Singleton, PhD, and Mike Nalls, PhD). PD data also included the National Institute of Neurological Disorders and Stroke (NINDS) Parkinson's Disease dataset provided through dbGaP accession phs001172.v1.p2 (PI Andrew Singleton, PhD, and John Hardy, PhD). PD data also included the Autopsy-Confirmed Parkinson Disease GWAS Consortium (APDGC) dataset provided through dbGaP accession (phs000394.v1.p1) (PI Jeffery Vance, MD, PhD, Collaborators: Thomas Beach, MD, PhD, Karen Marder, MD, MPH, Tatiana M. Foroud, Ted M. Dawson, MD, PhD, Matthew P. Frosch, MD, PhD, Dennis W. Dickson, MD, Samuel M. Goldman, MD, MPH, Harry Vinters, MD, Deborah Mash, PhD, James Leverenz, MD, Thomas J. Montine, MD, PhD, John Q. Trojanowski, MD, PhD, Vivianna Van Deerlin, MD, PhD) with funding sources: P50 NS071674-01S1 NIH, X01 HG006076-01 NIH, P50 NS072187-01S2 NIH, and genotyping center Johns Hopkins University Center for Inherited Disease Research (CIDR), Baltimore, MD, USA (HHSN268201100011I NHGRI and NIH). PD data also included the Genome-Wide Association Study of Parkinson Disease: Genes and Environment dataset provided through dbGaP accession (phs000196.v3.p1) (PI Haydeh Payami, PhD, and co-investigators: John Nutt, MD, Cyrus Zabetian, MS, MD, Stewart Factor, DO, Eric Molho, MD, Donald Higgins, MD) with funding source: 5R01NS36960-10 and genotyping center Johns Hopkins University Center for Inherited Disease Research (CIDR), Baltimore, MD, USA (HHSN268200782096C NIH). PD data also included the Parkinson's Disease Cognitive Genetics Consortium (PDCGC) Stage I, NeuroX Dataset (phs001664.v1.p1) for which we acknowledge the Pacific Northwest Udall Center (P50 NS062684). Healthy individuals from the Adult Change in Thought (ACT) study, which is a longitudinal prospective cohort study that began in 1994 (UO1 AG006781, UO1 HG004610, UO1 HG006375, U01 HG008657). PD data also included the dataset generated by the Wellcome Trust Case-Control Consortium 2 (WTCCC2) from UK patients with Parkinson's disease and UK control individuals from the 1958 Birth Cohort and National Blood Service (available through the EBI, accession EGAD00000000022 and EGAD00000000057). This study makes use of data generated by the Wellcome Trust Case-Control Consortium. A full list of the investigators who contributed to the generation of the data is available from www.wtccc.org.uk. Funding for the project was provided by the Wellcome Trust under award 076113, 085475 and 090355. Part of the data used in the preparation of this article were obtained from the AMP PD Knowledge Platform. For up-to-date information on the study, https://www.amp-pd.org.AMP PD - a public-private partnership - is managed by the FNIH and funded by Celgene, GSK, the Michael J. Fox Foundation for Parkinson's Research, the National Institute of Neurological Disorders and Stroke, Pfizer, Sanofi, and Verily. The AMP-AD data included clinical data and biosamples obtained from the Fox Investigation for New Discovery of Biomarkers (BioFIND), the Harvard Biomarker Study (HBS), the Parkinson's Progression Markers Initiative (PPMI), and the Parkinson's Disease Biomarkers Program (PDBP). BioFIND is sponsored by The Michael J. Fox Foundation for Parkinson's Research (MJFF) with support from the National Institute for Neurological Disorders and Stroke (NINDS). The BioFIND Investigators have not participated in reviewing the data analysis or content of the manuscript. For up-to-date information on the study, visit michaeljfox.org/biofin. Harvard NeuroDiscovery Biomarker Study (HBS) is a collaboration of HBS investigators funded through philanthropy and NIH and Non-NIH funding sources. A full list of HBS investigator can found at https://neurodiscovery.harvard.edu/biomarkers-core. The HBS Investigators have not participated in reviewing the data analysis or content of the manuscript. Parkinson's Progression Markers Initiative (PPMI) - a public-private partnership - is funded by the Michael J. Fox Foundation for Parkinson's Research and funding partners, including Abbvie, Allergan, Amathus therapeutics, Avid radiopharmaceuticals, Biogen, BioLegend, Bristol-Myers Squibb, Celgene, Denali, GE Healthcare, Genentech (Roche group), GSK, Janssen Neuroscience (Johnson-Johnson group), Lilly, Lundbeck, Merck, MSD, Pfizer, Piramal, Prevail, Roche, Sanofi Genzyme, Servier, Takeda, Teva, UCB, Verily, Voyager Therapeutics, Golub Capital. The PPMI Investigators have not participated in reviewing the data analysis or content of the manuscript. For up-to-date information on the study, visit www.ppmi-info.org. Parkinson's Disease Biomarker Program (PDBP) consortium is supported by the NINDS at the National Institutes of Health. A full list of PDBP investigators can be found at https://pdbp.ninds.nih.gov/policy. The PDBP Investigators have not participated in reviewing the data analysis or content of the manuscript. The McGill cohort was financially supported by grants from the Michael J. Fox Foundation, the Canadian Consortium on Neurodegeneration in Aging (CCNA), the Canada First Research Excellence Fund (CFREF), awarded to McGill University for the Healthy Brains for Healthy Lives initiative (HBHL), and Parkinson Canada. The access to part of the participants for this research has been made possible thanks to the Quebec Parkinson's Network (http://rpq-qpn.ca/en/). Acknowledgement for the use of the UK Biobank data This research has been conducted using the UK Biobank Resource under Application Number 45420.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The current study protocol was granted an exemption by the Stanford University institutional review board because the analyses were carried out on deidentified, off-the-shelf data; therefore, further informed consent was not required.

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

IPDGC NeuroX data available at: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000918.v1.p1 NINDS data available at: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001172.v1.p2 APDGC data available at: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/dataset.cgi?study_id=phs000394.v1.p1 NGRC data available at: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000196.v3.p1 EBI MERGE data available at: https://www.ebi.ac.uk/ega/studies/EGAS00000000034 UK Biobank data available at: http://biobank.ctsu.ox.ac.uk/crystal/ PDCGC data available at: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001664.v1.p1 ACT data available at: https://www.niagads.org/datasets/ng00034 For McGill please contact the Quebec Parkinson Network: http://rpq-qpn.ca/en/

https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000918.v1.p1

https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001172.v1.p2

https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/dataset.cgi?study_id=phs000394.v1.p1

https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000196.v3.p1

https://www.ebi.ac.uk/ega/studies/EGAS00000000034

http://biobank.ctsu.ox.ac.uk/crystal/

https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs001664.v1.p1

https://www.niagads.org/datasets/ng00034

http://rpq-qpn.ca/en/

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license.
Back to top
PreviousNext
Posted December 20, 2020.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Common X-chromosome variants are associated with Parkinson’s disease risk
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Common X-chromosome variants are associated with Parkinson’s disease risk
Yann Le Guen, Valerio Napolioni, Michael E. Belloy, Eric Yu, Lynne Krohn, Jennifer A. Ruskey, Ziv Gan-Or, Gabriel Kennedy, Sarah J. Eger, Michael D. Greicius
medRxiv 2020.12.18.20248459; doi: https://doi.org/10.1101/2020.12.18.20248459
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Common X-chromosome variants are associated with Parkinson’s disease risk
Yann Le Guen, Valerio Napolioni, Michael E. Belloy, Eric Yu, Lynne Krohn, Jennifer A. Ruskey, Ziv Gan-Or, Gabriel Kennedy, Sarah J. Eger, Michael D. Greicius
medRxiv 2020.12.18.20248459; doi: https://doi.org/10.1101/2020.12.18.20248459

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Neurology
Subject Areas
All Articles
  • Addiction Medicine (62)
  • Allergy and Immunology (142)
  • Anesthesia (46)
  • Cardiovascular Medicine (415)
  • Dentistry and Oral Medicine (70)
  • Dermatology (48)
  • Emergency Medicine (144)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (171)
  • Epidemiology (4861)
  • Forensic Medicine (3)
  • Gastroenterology (183)
  • Genetic and Genomic Medicine (676)
  • Geriatric Medicine (70)
  • Health Economics (192)
  • Health Informatics (630)
  • Health Policy (321)
  • Health Systems and Quality Improvement (206)
  • Hematology (85)
  • HIV/AIDS (156)
  • Infectious Diseases (except HIV/AIDS) (5343)
  • Intensive Care and Critical Care Medicine (331)
  • Medical Education (93)
  • Medical Ethics (24)
  • Nephrology (75)
  • Neurology (686)
  • Nursing (42)
  • Nutrition (115)
  • Obstetrics and Gynecology (126)
  • Occupational and Environmental Health (208)
  • Oncology (440)
  • Ophthalmology (140)
  • Orthopedics (36)
  • Otolaryngology (90)
  • Pain Medicine (35)
  • Palliative Medicine (16)
  • Pathology (129)
  • Pediatrics (194)
  • Pharmacology and Therapeutics (131)
  • Primary Care Research (84)
  • Psychiatry and Clinical Psychology (781)
  • Public and Global Health (1817)
  • Radiology and Imaging (325)
  • Rehabilitation Medicine and Physical Therapy (138)
  • Respiratory Medicine (255)
  • Rheumatology (86)
  • Sexual and Reproductive Health (69)
  • Sports Medicine (62)
  • Surgery (100)
  • Toxicology (23)
  • Transplantation (29)
  • Urology (37)